Medigene Investor Relations Material
Latest events
Status Update
Medigene
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Medigene AG
Access all reports
Medigene AG is a biotechnology company specializing in the development of T cell-based immunotherapies for cancer treatment. The company focuses on engineered T cell receptors (TCRs) and dendritic cell vaccines to enhance the body's immune response against tumors. Its research and development efforts aim to create innovative therapies that improve targeted cancer treatment options. The company is headquartered in Planegg, Germany, and its shares are listed on the Frankfurt Stock Exchange (FSE).
Key slides for Medigene AG
R&D Event
Medigene AG
Status Update
Medigene AG
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
MDG1
Country
🇩🇪 Germany